etrials Worldwide (Nasdaq: ) fell into the red in the third quarter, reporting a loss of $1.3 million, or 12 cents per share, on income of $4.1 million.
The provider of “eClinical” technology for clinical trials said income fell $300,000 from the same quarter in 2006 when it reported a profit of $400,000, or 3 cents per share.
Etrials’ board also authorized a $1 million buyback of etrials shares.
